Hsp110 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hsp110 (encoded by the HSPA4 gene) is a member of the Hsp70 family of molecular chaperones. It is also known as Hsp110, Hsp70-4, or APG-2. Hsp110 is one of the most abundant heat shock proteins and plays essential roles in protein quality control.
| Property |
Value |
| Protein Name |
Hsp110 / Hsp70-4 |
| Gene Symbol |
HSPA4 |
| UniProt ID |
P34932 |
| Molecular Weight |
94 kDa |
| Structure |
N-terminal ATPase domain, C-terminal substrate-binding domain |
| Expression |
Ubiquitous, high in brain, heart, testis |
| Subcellular Localization |
Cytoplasm, nucleus, organelles |
Hsp110 is a key component of the cellular protein quality control network:
- Chaperone Activity: Prevents aggregation of misfolded proteins and aids in refolding
- Protein Disaggregation: Works with Hsp70 and Hsp40 to extract proteins from aggregates
- Protein Degradation: Targets misfolded proteins to the proteasome or autophagy system
- Stress Response: Strongly induced by heat shock and other proteotoxic stresses
- Neuroprotection: Critical for neuronal survival under proteotoxic conditions
Hsp110 operates through sophisticated mechanisms:
- ATP-Dependent Cycling: N-terminal ATPase domain regulates substrate binding
- Hsp70/Hsp40 Collaboration: Forms functional complexes with Hsp70 and Hsp40
- Disaggregationase Activity: Can extract proteins from pre-formed aggregates
- Co-chaperone Interactions: Binds J-domain proteins for substrate delivery
- Nuclear Import/Export: Facilitates nuclear-cytoplasmic transport of proteins
- Alzheimer's Disease: Hsp110 may aid in clearing Aβ and tau aggregates
- Parkinson's Disease: Protects against α-synuclein toxicity
- Amyotrophic Lateral Sclerosis: Modifies SOD1 and TDP-43 aggregation
- Huntington's Disease: Helps clear mutant huntingtin aggregates
- Overexpressed in many cancers
- Confers resistance to chemotherapy
- Anti-apoptotic function through protein quality control
- Linked to insulin signaling and metabolic homeostasis
- May affect diabetes complications
- Hsp110 agonists: Activate chaperone function for neurodegeneration
- Hsp110 antagonists: Inhibit in cancer therapy to sensitize tumors
- Gene therapy: AAV-HSPA4 for neuroprotection
- Combination approaches: With Hsp70/Hsp40 modulators
- HSPA4 knockout mice: Embryonic lethal in some backgrounds
- Transgenic overexpression: Protects against protein aggregation
- Drosophila models: Loss causes neurodegeneration
- C. elegans: Used for aggregation studies
- Developing small molecule modulators of Hsp110
- Understanding disaggregase mechanism
- Biomarker development
- Gene therapy optimization
- Structure-function studies
The study of Hsp110 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.